• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by InflaRx N.V.

    4/17/23 4:00:10 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IFRX alert in real time by email
    SC 13G 1 g410232sc13g.htm

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    InflaRx N.V.

    (Name of Issuer)

     

    Common Shares, nominal value €0.12 per share

    (Title of Class of Securities)

     

     

     

    N44821101

    (CUSIP Number)

     

     

     

    April 5, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 Pages 
     

     

    CUSIP No. N44821101

     

    13G Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2

    Check the Appropriate Box if a Member of a Group*

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    3,000,000

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    3,000,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,000,000

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.5%

    12

    type of reporting person

     

    pN

     

     Page 2 of 8 Pages 
     

     

    CUSIP No. N44821101

     

    13G Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2

    Check the Appropriate Box if a Member of a Group*

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    3,000,000

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    3,000,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,000,000

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.5%

    12

    type of reporting person

     

    OO

     

     Page 3 of 8 Pages 
     

     

    CUSIP No. N44821101

     

    13G Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2

    Check the Appropriate Box if a Member of a Group*

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

     

    0

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    3,000,000

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

      8

    Shared Dispositive Power

     

    3,000,000

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    3,000,000

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.5%

    12

    type of reporting person

     

    IN

     

     Page 4 of 8 Pages 
     

     

    Item 1(a).Name of Issuer:

     

    InflaRx N.V., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    Winzerlaer Str. 2, 07745 Jena, Germany

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Shares, nominal value €0.12 per share (the “Common Shares”)

     

    Item 2(e).CUSIP Number: N44821101

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 3,000,000 shares of the Issuer’s Common Shares.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 3,000,000 shares of the Issuer’s Common Shares.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 3,000,000 shares of the Issuer’s Common Shares.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 Pages 
     

     

    The percentages used herein are based on 54,115,528 shares of Common Shares outstanding as of April 14, 2023, which includes (1) 44,703,763 shares of Common Shares outstanding as of December 31, 2022, as set forth in the Issuer’s Annual Report filed on Form 20-F that was filed with the Securities and Exchange Commission on March 22, 2023 and (2) 9,411,765 shares issued on April 14, 2023 as set forth in the Issuer’s Report of foreign issuer filed on Form 6-K that was filed with the Securities and Exchange Commission on April 13, 2023.

     

    (b)Percent of Class:

     

    Tang Capital Partners 5.5%
    Tang Capital Management 5.5%
    Kevin Tang 5.5%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 3,000,000 shares
    Tang Capital Management 3,000,000 shares
    Kevin Tang 3,000,000 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 3,000,000 shares
    Tang Capital Management 3,000,000 shares
    Kevin Tang 3,000,000 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

     Page 6 of 8 Pages 
     

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 Pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: April 17, 2023  

     

     

    TANG CAPITAL PARTNERS, LP

     

    By: Tang Capital Management, LLC, its General Partner

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    TANG CAPITAL MANAGEMENT, LLC

     

     

    By: /s/ Kevin Tang  
      Kevin Tang, Manager  

     

     

    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

     

    Get the next $IFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IFRX

    DatePrice TargetRatingAnalyst
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2023$8.00Neutral → Buy
    Guggenheim
    2/28/2022Buy → Neutral
    Guggenheim
    11/8/2021$14.00 → $15.00Strong Buy
    Raymond James
    10/28/2021$14.00Outperform → Strong Buy
    Raymond James
    8/6/2021$11.00 → $10.00Outperform
    Raymond James
    8/6/2021$2.80 → $2.50Underperform
    Credit Suisse
    More analyst ratings

    $IFRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

      Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline addressing multiple sizable marketsInterim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG), to determine trial size adaptation or futility, remains on schedule with a recommendation expected to be announced at the end of May to early JuneTopline data for INF904 Phase 2a trial in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025Cash, cash equivalents and marketable securities totaled

      5/7/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report First Quarter 2025 Results on May 7, 2025

      JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

      4/30/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

      Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025Multiple data presentations at AAD 2025 highlighting the potential of vilobelimab in reducing systemic inflammationCash, cash equivalents and marketable securities of €5

      3/20/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by InflaRx N.V.

      SC 13G - InflaRx N.V. (0001708688) (Subject)

      4/24/23 4:47:08 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by InflaRx N.V.

      SC 13G - InflaRx N.V. (0001708688) (Subject)

      4/17/23 4:00:10 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

      SC 13G/A - InflaRx N.V. (0001708688) (Subject)

      2/13/23 12:01:42 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    SEC Filings

    See more
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      5/7/25 7:53:43 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      4/24/25 5:00:36 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      4/3/25 7:31:25 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Leadership Updates

    Live Leadership Updates

    See more

    $IFRX
    Financials

    Live finance-specific insights

    See more

    $IFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InflaRx Appoints Jan Medina as Head of Investor Relations

      JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We are delighted to welcome Jan to our team. His experience, proven track record and deep network with investors and capital mark

      2/22/24 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

      Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx's portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affai

      6/28/23 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report First Quarter 2025 Results on May 7, 2025

      JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

      4/30/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

      JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned. InflaRx also announced that it will participate in two investor conferences. Details are as follows: Leerink Global Healthcare ConferenceMarch 9 - 12, 2025 in Miami Beach, FL InflaRx will conduct a fireside chat at the conference on March 10 at 10:40 AM ET and will participate in one-on-one-investor meetings. A link to regis

      2/25/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

      JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third quarter 2024 financial and operating results on Friday, November 8, 2024, before the market opens. No conference call is planned. In addition, InflaRx will participate in the following investor event: Guggenheim Securities Inaugural Healthcare Innovation ConferenceNovember 11-13, 2024, Boston, MAFireside chat: November 11th, 11:00 am ET A link to register for the fireside chat live stream and its replay is available here. The company will also participa

      10/31/24 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on InflaRx with a new price target

      Cantor Fitzgerald initiated coverage of InflaRx with a rating of Overweight and set a new price target of $10.00

      4/29/25 8:10:45 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx upgraded by Guggenheim with a new price target

      Guggenheim upgraded InflaRx from Neutral to Buy and set a new price target of $8.00

      4/5/23 11:33:25 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx downgraded by Guggenheim

      Guggenheim downgraded InflaRx from Buy to Neutral

      2/28/22 11:38:01 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care